Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by AstraZeneca < Previous 1 2 3 4 5 6 7 Next > CALQUENCE combination regimen demonstrated statistically significant and clinically meaningful improvement in progression-free survival in 1st-line mantle cell lymphoma in ECHO Phase III trial May 02, 2024 From AstraZeneca Via Business Wire Tickers AZN AstraZeneca unveils latest research across key respiratory and immune-mediated diseases at ATS 2024 showcasing strength of its broad pipeline and portfolio May 01, 2024 From AstraZeneca Via Business Wire Tickers AZN ENHERTU® (fam-trastuzumab deruxtecan-nxki) improved PFS in HER2-low and ultralow April 29, 2024 From AstraZeneca Via Business Wire Tickers AZN Q1 2024 results April 25, 2024 From AstraZeneca Via Business Wire Tickers AZN IMFINZI® (durvalumab) plus chemotherapy doubled overall survival rate at three years for patients with advanced biliary tract cancer in TOPAZ-1 Phase III trial April 16, 2024 From AstraZeneca Via Business Wire Tickers AZN FASENRA approved for treatment of children aged 6 to 11 with severe asthma April 11, 2024 From AstraZeneca Via Business Wire Tickers AZN ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US as first tumor-agnostic HER2-directed therapy for previously treated patients with metastatic HER2-positive solid tumors April 05, 2024 From AstraZeneca Via Business Wire Tickers AZN IMFINZI® (durvalumab) significantly improved overall survival and progression-free survival for patients with limited-stage small cell lung cancer in ADRIATIC Phase III trial April 05, 2024 From AstraZeneca Via Business Wire Tickers AZN Datopotamab deruxtecan Biologics License Application accepted in the US for patients with previously treated metastatic HR-positive, HER2-negative breast cancer April 02, 2024 From AstraZeneca Via Business Wire Tickers AZN AstraZeneca to acquire Fusion to accelerate the development of next-generation radioconjugates to treat cancer March 19, 2024 From AstraZeneca Via Business Wire Tickers AZN AstraZeneca caps patient out-of-pocket costs at $35 per month for its US inhaled respiratory portfolio March 18, 2024 From AstraZeneca Via Business Wire Tickers AZN AstraZeneca announces initiation of THARROS – a Phase III clinical trial investigating the potential of BREZTRI to improve cardiopulmonary outcomes in people with COPD March 13, 2024 From AstraZeneca Via Business Wire Tickers AZN MANDARA Phase III data published in New England Journal of Medicine show remission is an achievable goal in eosinophilic granulomatosis with polyangiitis (EGPA) with FASENRA February 23, 2024 From AstraZeneca Via Business Wire Tickers AZN Datopotamab deruxtecan Biologics License Application accepted in the US for patients with previously treated advanced nonsquamous non-small cell lung cancer February 19, 2024 From AstraZeneca Via Business Wire Tickers AZN TAGRISSO® (osimertinib) demonstrated overwhelming efficacy benefit for patients with unresectable, Stage III EGFR-mutated lung cancer in LAURA Phase III trial February 19, 2024 From AstraZeneca Via Business Wire Tickers AZN TAGRISSO® (osimertinib) with the addition of chemotherapy approved in the US for patients with EGFR-mutated advanced lung cancer February 16, 2024 From AstraZeneca Via Business Wire Tickers AZN AstraZeneca Full year and Q4 2023 Financial Results February 08, 2024 From AstraZeneca Via Business Wire Tickers AZN AstraZeneca expands US manufacturing footprint to accelerate ambitions in next-generation cell therapy discovery and development February 06, 2024 From AstraZeneca Via Business Wire Tickers AZN ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Priority Review in the US for patients with metastatic HER2-positive solid tumors January 29, 2024 From AstraZeneca Via Business Wire Tickers AZN AIRSUPRA® (albuterol/budesonide) now available as the first and only FDA-approved anti-inflammatory rescue option for asthma January 22, 2024 From AstraZeneca Via Business Wire Tickers AZN IMFINZI® (durvalumab) plus transarterial chemoembolization (TACE) and bevacizumab reduced the risk of disease progression or death by 23% vs. TACE in liver cancer eligible for embolization January 19, 2024 From AstraZeneca Via Business Wire Tickers AZN AstraZeneca to acquire Gracell, furthering cell therapy ambition across oncology and autoimmune diseases December 26, 2023 From AstraZeneca Via Business Wire Tickers AZN GRCL WAINUA™ (eplontersen) Granted First-Ever Regulatory Approval in the US for the Treatment of Adults With Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis December 21, 2023 From AstraZeneca Via Business Wire Tickers AZN AstraZeneca to Acquire Icosavax, Including Potential First-in-class RSV and hMPV Combination Vaccine With Positive Phase II Data December 12, 2023 From AstraZeneca Via Business Wire Tickers AZN AstraZeneca advances scientific leadership in hematology at ASH 2023 November 29, 2023 From AstraZeneca Via Business Wire Tickers AZN AstraZeneca launches Evinova, a health-tech business to accelerate innovation across the life sciences sector, the delivery of clinical trials and better health outcomes November 20, 2023 From AstraZeneca Via Business Wire Tickers AZN TRUQAP™ (capivasertib) plus fulvestrant approved in the US for patients with advanced HR-positive breast cancer November 17, 2023 From AstraZeneca Via Business Wire Tickers AZN IMFINZI® (durvalumab) plus bevacizumab met primary endpoint for progression-free survival in liver cancer eligible for embolization in EMERALD-1 Phase III trial November 09, 2023 From AstraZeneca Via Business Wire Tickers AZN AstraZeneca to leverage its global industrial-scale manufacturing and digital capabilities to boost US renewable natural gas productivity November 08, 2023 From AstraZeneca Via Business Wire Tickers AZN Zibotentan/dapagliflozin combination demonstrated significant albuminuria reduction in patients with chronic kidney disease and proteinuria in ZENITH-CKD Phase IIb trial November 03, 2023 From AstraZeneca Via Business Wire Tickers AZN < Previous 1 2 3 4 5 6 7 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
